Tyrosine kinase inhibitors in cancer therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Manning, 2002, The protein kinase complement of the human genome, Science, 298, 1912, 10.1126/science.1075762
Krupa, 2002, The repertoire of protein kinases encoded in the draft version of the human genome: atypical variations and uncommon domain combinations, Genome Biol., 3, 10.1186/gb-2002-3-12-research0066
Robinson, 2000, The protein tyrosine kinase family of the human genome, Oncogene, 19, 5548, 10.1038/sj.onc.1203957
Schlessinger, 2000, Cell signaling by receptor tyrosine kinases, Cell, 103, 211, 10.1016/S0092-8674(00)00114-8
Hunter, 1998, The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease, Philos. Trans. R. Soc. Lond., B Biol. Sci., 353, 583, 10.1098/rstb.1998.0228
Weiner, 2000, Growth factor receptor tyrosine kinases: cell adhesion kinase family suggests a novel signaling mechanism in cancer, Cancer Invest., 18, 544, 10.3109/07357900009012194
Ben-Bassat, 2001, Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy, Curr. Opin. Invest. Drugs, 2, 1539
Lee, 2002, RET receptor tyrosine kinase isoforms in kidney function and disease, Oncogene, 21, 5582, 10.1038/sj.onc.1205741
Grandis, 1998, Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells, J. Cell. Biochem., 69, 55, 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U
Tandon, 1989, HER-2/neu oncogene protein and prognosis in breast cancer, J. Clin. Oncol., 7, 1120, 10.1200/JCO.1989.7.8.1120
Meden, 1997, Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor, Eur. J. Obstet. Gynecol. Reprod. Biol., 71, 173, 10.1016/S0301-2115(96)02630-9
Sadasivan, 1993, Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer, J. Urol., 150, 126, 10.1016/S0022-5347(17)35413-7
Selvaggi, 2002, HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival, Cancer, 94, 2669, 10.1002/cncr.10531
Zhou, 2003, Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification, J. Pediatr. Hematol. Oncol., 25, 27, 10.1097/00043426-200301000-00007
Taniguchi, 1999, Effect of c-KIT mutation on prognosis of gastrointestinal stromal tumors, Cancer Res., 59, 4297
Care, 2003, Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias, Br. J. Haematol., 121, 775, 10.1046/j.1365-2141.2003.04362.x
Naeem, 2002, Analysis of c-KIT protein expression in small-cell lung carcinoma and its implication for prognosis, Hum. Pathol., 33, 1182, 10.1053/hupa.2002.129199
Peters, 2003, IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer, Virchows Arch., 10.1007/s00428-003-0856-5
Schnittger, 2002, Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease, Blood, 100, 59, 10.1182/blood.V100.1.59
Fox, 2001, Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs, Lancet Oncol., 2, 278, 10.1016/S1470-2045(00)00323-5
Arinaga, 2003, Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma, Cancer, 97, 457, 10.1002/cncr.11073
Parr, 2003, Quantitative analysis of lymphangiogenic markers in human colorectal cancer, Int. J. Oncol., 23, 533
Eggert, 2000, Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma, Klin. Padiatr., 212, 200, 10.1055/s-2000-9677
Baykal, 2003, Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas, Gynecol. Oncol., 88, 123, 10.1016/S0090-8258(02)00073-2
Oda, 2000, Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-Met correlates with poor prognosis in synovial sarcoma, Hum. Pathol., 31, 185, 10.1016/S0046-8177(00)80218-X
Ueki, 1997, Expression of hepatocyte growth factor and its receptor c-Met proto-oncogene in hepatocellular carcinoma, Hepatology, 25, 862, 10.1002/hep.510250413
Rochlitz, 1999, Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK), Leukemia, 13, 1352, 10.1038/sj.leu.2401484
Lin, 1999, Tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer, Clin. Cancer Res., 5, 1745
Verstovsek, 2002, Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia, Cancer, 94, 1517, 10.1002/cncr.10363
Homer, 2002, Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma, Head Neck, 24, 773, 10.1002/hed.10123
Gascoyne, 1999, Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma, Blood, 93, 3913, 10.1182/blood.V93.11.3913
Aligayer, 2002, Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis, Cancer, 94, 344, 10.1002/cncr.10221
Olavarria, 2001, Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia, Blood, 97, 1560, 10.1182/blood.V97.6.1560
O'Dwyer, 2002, Multifaceted approach to the treatment of BCR-ABL-positive leukemias, Oncologist, 7, 30, 10.1634/theoncologist.7-suppl_1-30
Gleissner, 2002, Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis, Blood, 99, 1536, 10.1182/blood.V99.5.1536
Miyazaki, 2003, FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma, Br. J. Cancer, 89, 140, 10.1038/sj.bjc.6601050
Toyama, 2003, Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer, Cancer Lett., 189, 97, 10.1016/S0304-3835(02)00463-9
Al-Obeidi, 2000, Development of inhibitors for protein tyrosine kinases, Oncogene, 19, 5690, 10.1038/sj.onc.1203926
Fabbro, 2002, Protein kinases as targets for anticancer agents: from inhibitors to useful drugs, Pharmacol. Ther., 93, 79, 10.1016/S0163-7258(02)00179-1
Levitzki, 2002, Tyrosine kinases as targets for cancer therapy, Eur. J. Cancer, 38, S11, 10.1016/S0959-8049(02)80598-6
Stamos, 2002, Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor, J. Biol. Chem., 277, 46265, 10.1074/jbc.M207135200
Laird, 2003, Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents, Expert Opin. Invest. Drugs, 12, 51, 10.1517/13543784.12.1.51
Fry, 2003, Mechanism of action of erbB tyrosine kinase inhibitors, Exp. Cell Res., 284, 131, 10.1016/S0014-4827(02)00095-2
Denny, 2002, Irreversible inhibitors of the erbB family of protein tyrosine kinases, Pharmacol. Ther., 93, 253, 10.1016/S0163-7258(02)00194-8
Mellinghoff, 2002, Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts, Cancer Res., 62, 5254
Slichenmyer, 2001, CI-1033, a pan-erbB tyrosine kinase inhibitor, Semin. Oncol., 28, 80, 10.1016/S0093-7754(01)90285-4
Hoekman, 2001, SU6668, a multitargeted angiogenesis inhibitor, Cancer J., 7, S134
Buchdunger, 2002, Pharmacology of imatinib (STI571), Eur. J. Cancer, 38, S28, 10.1016/S0959-8049(02)80600-1
Nishimura, 2003, Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c, Oncogene, 22, 4074, 10.1038/sj.onc.1206498
Glossmann, 1981, Quercetin inhibits tyrosine phosphorylation by the cyclic nucleotide-independent, transforming protein kinase, pp60src, Naunyn-Schmiedeberg's Arch. Pharmacol., 317, 100, 10.1007/BF00506266
Akiyama, 1987, Genistein, a specific inhibitor of tyrosine-specific protein kinases, J. Biol. Chem., 262, 5592, 10.1016/S0021-9258(18)45614-1
Mendelsohn, 2002, Targeting the epidermal growth factor receptor for cancer therapy, J. Clin. Oncol., 20, 1S
Farah, 1998, The development of monoclonal antibodies for the therapy of cancer, Crit. Rev. Eukaryotic Gene Expression, 8, 321, 10.1615/CritRevEukarGeneExpr.v8.i3-4.50
Hudson, 1999, Recombinant antibody constructs in cancer therapy, Curr. Opin. Immunol., 11, 548, 10.1016/S0952-7915(99)00013-8
Prewett, 1999, Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors, Cancer Res., 59, 5209
Posey, 2003, A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma, Clin. Cancer Res., 9, 1323
Zwick, 2002, Receptor tyrosine kinases as targets for anticancer drugs, Trends Mol. Med., 8, 17, 10.1016/S1471-4914(01)02217-1
Madhusudan, 2002, Drug inhibition of angiogenesis, Curr. Opin. Pharmacol., 2, 403, 10.1016/S1471-4892(02)00184-4
Cross, 2001, FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition, Trends Pharmacol. Sci., 22, 201, 10.1016/S0165-6147(00)01676-X
Blaskovich, 2000, Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice, Nat. Biotechnol., 18, 1065, 10.1038/80257
Chen, 1999, Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies, J. Clin. Pharmacol., 39, 1248, 10.1177/00912709922012051
Murphy, 1995, Targeting diphtheria toxin to growth factor receptors, Semin. Cancer Biol., 6, 259, 10.1006/scbi.1995.0034
Wild, 2000, Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells, Br. J. Cancer, 83, 1077, 10.1054/bjoc.2000.1439
Disis, 2001, Clinical translation of peptide-based vaccine trials: the HER-2/neu model, Crit. Rev. Immunol., 21, 263, 10.1615/CritRevImmunol.v21.i1-3.170
Disis, 1999, Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine, Clin. Cancer Res., 5, 1289
Disis, 2002, Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers, Blood, 99, 2845, 10.1182/blood.V99.8.2845
Zeng, 2002, Lack of toxicity of EGFR antisense gene therapy, J. Exp. Ther. Oncol., 2, 174, 10.1046/j.1359-4117.2002.01033.x
Andrews, 2001, Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas, J. Clin. Oncol., 19, 2189, 10.1200/JCO.2001.19.8.2189
Endo, 2000, TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo, Gene Ther., 7, 1906, 10.1038/sj.gt.3301315
Mousses, 2003, Harnessing the power of RNA interference to advance anticancer drug development, Mol. Cancer Ther., 2, 217
Zhang, 2003, Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer, Biochem. Biophys. Res. Commun., 303, 1169, 10.1016/S0006-291X(03)00495-9
Dancey, 2003, Issues and progress with protein kinase inhibitors for cancer treatment, Nat. Rev., Drug Discov., 2, 296, 10.1038/nrd1066
Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells, Nat. Med., 2, 561, 10.1038/nm0596-561
Buchdunger, 1996, Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative, Cancer Res., 56, 100
Manley, 2002, Imatinib: a selective tyrosine kinase inhibitor, Eur. J. Cancer, 38, S19, 10.1016/S0959-8049(02)80599-8
Deininger, 1997, The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells, Blood, 90, 3691, 10.1182/blood.V90.9.3691
Kasper, 1999, Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors, Cancer Chemother. Pharmacol., 44, 433, 10.1007/s002800051001
le Coutre, 1999, In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor, J. Natl. Cancer Inst., 91, 163, 10.1093/jnci/91.2.163
Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N. Engl. J. Med., 344, 1031, 10.1056/NEJM200104053441401
Druker, 2001, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, N. Engl. J. Med., 344, 1038, 10.1056/NEJM200104053441402
Druker, 2002, Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy, Eur. J. Cancer, 38, S70, 10.1016/S0959-8049(02)80606-2
Johnson, 2003, Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, Clin. Cancer Res., 9, 1972
Wisniewski, 2002, Characterization of potent inhibitors of the BCR-ABL and the c-KIT receptor tyrosine kinases, Cancer Res., 62, 4244
Demetri, 2002, Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571), Eur. J. Cancer, 38, S52, 10.1016/S0959-8049(02)80603-7
Rubin, 2001, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors, Cancer Res., 61, 8118
Tuveson, 2001, STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications, Oncogene, 20, 5054, 10.1038/sj.onc.1204704
Dagher, 2002, Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors, Clin. Cancer Res., 8, 3034
van Oosterom, 2002, Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group, Eur. J. Cancer, 38, S83, 10.1016/S0959-8049(02)80608-6
Krystal, 2000, The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth, Clin. Cancer Res., 6, 3319
Soria, 2003, Imatinib in small cell lung cancer, Lung Cancer, 41, S49, 10.1016/S0169-5002(03)00142-9
Gunby, 2003, Sensitivity to imatinib but low frequency of the TEL/PDGFRb fusion protein in chronic myelomonocytic leukemia, Haematologica, 88, 408
Cortes, 2003, Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders, Cancer, 97, 2760, 10.1002/cncr.11416
Sawyers, 2002, Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor, J. Clin. Oncol., 20, 3568, 10.1200/JCO.2002.20.17.3568
Kilic, 2000, Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class, Cancer Res., 60, 5143
Pietras, 2001, Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors, Cancer Res., 61, 2929
Gleich, 2002, Treatment of hypereosinophilic syndrome with imatinib mesilate, Lancet, 359, 1577, 10.1016/S0140-6736(02)08505-7
Cools, 2003, A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome, N. Engl. J. Med., 348, 1201, 10.1056/NEJMoa025217
Pardanani, 2003, CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy, Blood, 102, 3093, 10.1182/blood-2003-05-1627
Grunwald, 2003, Developing inhibitors of the epidermal growth factor receptor for cancer treatment, J. Natl. Cancer Inst., 95, 851, 10.1093/jnci/95.12.851
Sirotnak, 2003, Studies with ZD1839 in preclinical models, Semin. Oncol., 30, 12, 10.1053/sonc.2003.50028
Hirata, 2002, ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase, Cancer Res., 62, 2554
Ciardiello, 2000, Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor, Clin. Cancer Res., 6, 2053
Wells, 2000, Tumor invasion: role of growth factor-induced cell motility, Adv. Cancer Res., 78, 31, 10.1016/S0065-230X(08)61023-4
Anderson, 2000, Effects of ZD1839 (Iressa), a novel EGF receptor tyrosine kinase inhibitor on breast cancer cell proliferation and invasiveness, Breast Cancer Res. Treat., 64
Sirotnak, 2000, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase, Clin. Cancer Res., 6, 4885
Houghton, 2000, Evaluation of ZD1839 (Iressa) alone or in combination with Irinotecan (CPT-11) against pediatric solid tumour xenografts, Clin. Cancer Res., 6, 4542s
Ranson, 2002, ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial, J. Clin. Oncol., 20, 2240, 10.1200/JCO.2002.10.112
Negoro, 2001, Final results of a phase I intermittent dose-escalation trial of ZD1839 (‘Iressa’) in Japanese patients with various solid tumours [abstract no. 1292], Proc. ASCO, 20
Baselga, 2000, Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability [abstract no. 686], Proc. ASCO, 19
Goss, 2001, Final results of the dose escalation phase of a phase I pharmacokinetic (PK), pharmacodynamic (PD) and biological activity study of ZD1839: NCIC CTG Ind.122 [abstract no. 335], Proc. ASCO, 20
Albanell, 2002, Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition, J. Clin. Oncol., 20, 110, 10.1200/JCO.20.1.110
Fukuoka, 2002, Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1) [abstract no. 1188], Proc. ASCO, 21
Kris, 2002, A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who failed platinum- and docetaxel-based regimens (IDEAL 2) [abstract no. 1166], Proc. ASCO, 21
Ronald, 2003, Geftinib (Iressa): the first effective EGFR-targeted agent in non-small cell lung cancer
Ranson, 2003, Skin toxicity is not a clinically meaningful prognostic marker for tumor response to geftinib (‘Iressa’, ZD1839) in pre-treated patients with advanced non-small-cell lung cancer
Giaccone, 2002, A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1), Ann. Oncol., 13, 2
Johnson, 2002, ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2), Ann. Oncol., 13, 127
Sridhar, 2003, Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer, Lancet Oncol., 4, 397, 10.1016/S1470-2045(03)01137-9
Moyer, 1997, Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase, Cancer Res., 57, 4838
Pollack, 1999, Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice, J. Pharmacol. Exp. Ther., 291, 739
Akita, 2003, Preclinical studies with erlotinib (Tarceva), Semin. Oncol., 30, 15, 10.1016/S0093-7754(03)70011-6
Ng, 2002, Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma, Mol. Cancer Ther., 1, 777
Herbst, 2003, Erlotinib (Tarceva): an update on the clinical trial program, Semin. Oncol., 30, 34, 10.1016/S0093-7754(03)70013-X
Hidalgo, 2001, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J. Clin. Oncol., 19, 3267, 10.1200/JCO.2001.19.13.3267
Grunwald, 2003, Development of the epidermal growth factor receptor inhibitor OSI-774, Semin. Oncol., 30, 23, 10.1016/S0093-7754(03)70022-0
Allen, 2002, Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer, Semin Oncol., 29, 11, 10.1053/sonc.2002.34049
Fry, 1998, Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor, Proc. Natl. Acad. Sci. U. S. A., 95, 12022, 10.1073/pnas.95.20.12022
Gieseg, 2001, Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033, Anticancer Drugs, 12, 683, 10.1097/00001813-200109000-00007
Rusnak, 2001, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo, Mol. Cancer Ther., 1, 85
Bruns, 2000, Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma, Cancer Res., 60, 2926
Barbacci, 2003, The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells, Cancer Res., 63, 4450
Fong, 1999, SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, Cancer Res., 59, 99
Zhu, 2002, Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics, Curr. Cancer Drug Targets, 2, 135, 10.2174/1568009023333881
Smolich, 2001, The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-KIT) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts, Blood, 97, 1413, 10.1182/blood.V97.5.1413
Kuenen, 2003, Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma, Clin. Cancer Res., 9, 1648
Kuenen, 2002, Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors, J. Clin. Oncol., 20, 1657, 10.1200/JCO.20.6.1657
Laird, 2000, SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors, Cancer Res., 60, 4152
Shaheen, 2001, Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms, Cancer Res., 61, 1464
Fabbro, 2001, Su-6668. SUGEN, Curr. Opin. Invest. Drugs, 2, 1142
Drevs, 2000, Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model, Cancer Res., 60, 4819
Wood, 2000, PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration, Cancer Res., 60, 2178
Wedge, 2002, ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration, Cancer Res., 62, 4645
Miknyoczki, 1999, The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma, Clin. Cancer Res., 5, 2205
George, 1999, Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555), Cancer Res., 59, 2395
Carlomagno, 2002, ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases, Cancer Res., 62, 7284
Kelly, 2002, CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML), Cancer Cell, 1, 421, 10.1016/S1535-6108(02)00070-3
O'Farrell, 2003, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood, 101, 3597, 10.1182/blood-2002-07-2307
Spiekermann, 2003, The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3, Blood, 101, 1494, 10.1182/blood-2002-04-1045
Weisberg, 2002, Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412, Cancer Cell, 1, 433, 10.1016/S1535-6108(02)00069-7
Levis, 2002, A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo, Blood, 99, 3885, 10.1182/blood.V99.11.3885
Susva, 2000, Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?, Trends Pharmacol. Sci., 21, 489, 10.1016/S0165-6147(00)01567-4
Sawyer, 2003, A new class of small-molecule therapeutics for osteolytic bone metastasis: discovery of novel bone-targeted src tyrosine kinase inhibitors having potent in vitro and in vivo activities [abstract no. 977], Proc. ASCO, 22
Sattler, 2003, The novel small molecule drug SU-MI-2 induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase [abstract no. 1005], Proc. AACR, 44
Saijo, 2003, Mechanisms of ZD1839 resistance and ZD1839 induced pulmonary fibrosis
Paterson, 2003, Is there a cloud in the silver lining for imatinib?, Br. J. Cancer, 88, 983, 10.1038/sj.bjc.6600828
Koizumi, 2003, Mechanism of resistance to epidermal growth factor receptor inhibitor ZD1839: a role for inhibiting phosphorylation of EGFR at Tyr 1068 [abstract no. 1001], Proc. AACR, 44
Jones, 2003, Acquired resistance to geftinib (‘Iressa’, ZD1839) in breast cancer cells result from increased IGF1-R signalling and generates cross-resistance to trastuzumab
Soler-Perez, 2003, Molecular mechanisms of resistance to the HER1/EGFR tyrosine kinase inhibitor erlotinib HCI in human cell lines [abstract no. 762], Proc. ASCO, 22
Scappaticci, 2002, Mechanisms and future directions for angiogenesis-based cancer therapies, J. Clin. Oncol., 20, 3906, 10.1200/JCO.2002.01.033
Sawyers, 2003, Opportunities and challenges in the development of kinase inhibitor therapy for cancer, Genes Dev., 17, 2998, 10.1101/gad.1152403
Duyster, 2001, Translocations involving anaplastic lymphoma kinase (ALK), Oncogene, 20, 5623, 10.1038/sj.onc.1204594
Schmidt, 1999, Novel mutations of the MET proto-oncogene in papillary renal carcinomas, Oncogene, 18, 2343, 10.1038/sj.onc.1202547
Eng, 1999, RET proto-oncogene in the development of human cancer, J. Clin. Oncol., 17, 380, 10.1200/JCO.1999.17.1.380
Parsons, 2003, PTEN and cancer, Methods Mol. Biol., 222, 147
Shimizu, 1999, The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB, Cancer Res., 59, 3719
Bardelli, 2003, Mutational analysis of the tyrosine kinome in colorectal cancers, Science, 300, 949, 10.1126/science.1082596
Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N. Engl. J. Med., 349, 427, 10.1056/NEJMoa021491
Nagar, 2002, Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571), Cancer Res., 62, 4236
Shah, 2002, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia, Cancer Cell, 2, 117, 10.1016/S1535-6108(02)00096-X
Branford, 2003, Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis, Blood, 102, 276, 10.1182/blood-2002-09-2896
Gorre, 2002, Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia, Curr. Opin. Hematol., 9, 303, 10.1097/00062752-200207000-00007